Severin Schwan, chairman of Swiss pharmaceutical powerhouse Roche, delivered a rare and sharply critical assessment of U.S. trade policy on Thursday, describing Washington’s use of tariff threats to force drug price reductions as “cold-blooded blackmail.”

His comments shed light on the intense pressure major international drugmakers face amid the Trump administration’s aggressive push to reshape the pharmaceutical trade industry. Schwan was referring to a late-2025 agreement in which Roche agreed to significantly lower prices for its medicines in the United States after U.S. officials threatened to impose steep tariffs, reportedly as high as 200%, on pharmaceutical imports.

Speaking at an event in the Swiss city of Interlaken, he made no effort to soften his view of the negotiations.

“If someone points a gun at you and says ‘if you don’t sign, there’ll be 200% tariffs tomorrow’, I wouldn’t necessarily describe that as a deal. So in a legal sense that’s perhaps an agreement, but it’s basically cold-blooded blackmail,” he said.

The remarks expose the growing friction between global pharmaceutical companies and the Trump administration, which has repeatedly argued that foreign firms have taken advantage of the U.S. market to charge American consumers excessively high prices. By wielding the threat of tariffs, the administration has sought both immediate price concessions and longer-term shifts toward increased domestic drug manufacturing.

Beyond the immediate dispute, Schwan identified rising protectionism from both the United States and China as Roche’s single biggest geopolitical concern. This assessment carries significant weight given Roche’s global footprint. As one of the world’s largest biotech and diagnostics companies, Roche operates extensive research, development, and manufacturing networks across Europe, North America, and Asia.

Fragmentation of global trade rules, export controls on critical materials, and retaliatory measures threaten to disrupt these carefully optimized supply chains and slow the pace of innovation.

The U.S.-China strategic rivalry has already complicated matters for the industry. Beijing has tightened controls on rare earth minerals and pharmaceutical ingredients, while Washington has expanded scrutiny of supply chain security and intellectual property practices.

For a company like Roche, which relies on cross-border collaboration for everything from clinical trials to advanced manufacturing, this dual pressure from the world’s two largest economies creates a challenging operating environment.

Schwan’s unusually candid criticism reflects broader frustration across the European and international pharmaceutical sector. Many companies have quietly accepted price cuts or localized production commitments to avoid tariffs, but executives worry about the long-term consequences.

Forced price reductions in the lucrative U.S. market, which often accounts for a disproportionate share of global profits for innovative medicines, could reduce the financial resources available for research and development. This is particularly concerning at a time when the industry is investing heavily in next-generation therapies such as antibody-drug conjugates, personalized medicine, and advanced diagnostics.

The Trump administration’s approach, while politically popular domestically, risks undermining the incentive structure that has driven decades of medical progress. Pharmaceutical innovation is extraordinarily expensive and risky, with the vast majority of development programs failing to reach the market. High prices in the United States have historically helped subsidize global R&D.

Industry leaders have expressed concern that significant and sustained price erosion could slow the pipeline of new treatments for cancer, Alzheimer’s, rare diseases, and other conditions.

Roche has long positioned itself as a leader in oncology, immunology, and diagnostics. The company’s ability to maintain robust innovation depends on stable and predictable access to major markets. Thus, Schwan is suggesting that while Roche complied with U.S. demands to avoid tariffs, the experience has left a sour taste and heightened concerns about future unpredictability in trade policy.

The episode also illustrates the limited leverage many foreign companies have when dealing with the U.S. market. With America representing roughly 40-50% of global pharmaceutical revenue for many innovative drugs, walking away from negotiations is rarely a realistic option. This dynamic gives Washington considerable negotiating power but also risks straining transatlantic relations and encouraging companies to accelerate supply chain diversification — moves that carry their own costs.

Looking ahead, pharmaceutical companies are likely to adopt a multi-pronged strategy: engaging constructively with U.S. policymakers where possible, while quietly accelerating efforts to localize production, diversify supply chains, and strengthen relationships in other growth markets such as Europe, China, and emerging economies.

For Roche specifically, the focus remains on executing its rich pipeline and maintaining leadership in key therapeutic areas. However, Schwan’s remarks serve as a public signal that the company, and by extension much of the industry, views the current trade environment as unsustainable and potentially damaging to long-term innovation.